Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Fast-Acting Mealtime Insulin

Novo Nordisk news release; 2017 Sep 29

The FDA has approved Fiasp (insulin aspart injection) 100 units/mL, a fast-acting mealtime insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes, available from Novo Nordisk, Plainsboro NJ.

Indications: Fiasp is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

Dosage/administration: Can be dosed at the beginning of a meal or within 20 minutes after starting a meal. Individualize and adjust dosage based on route of administration, individual’s metabolic needs, blood glucose monitoring results, and glycemic control goal.

Adverse reactions: Adverse reactions include hypoglycemia, allergic reactions, hypersensitivity, injection site reactions, lipodystrophy, and weight gain.

Citation:

Novo Nordisk receives FDA approval for Fiasp, a new fast-acting mealtime insulin. [news release]. Novo Nordisk, Plainsboro, NJ. September 29. 2017. http://press.novonordisk-us.com/2017-09-29-Novo-Nordisk-Receives-FDA-Approval-for-Fiasp-R-a-New-Fast-Acting-Mealtime-Insulin. Accessed October 8, 2017.